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Abstract
The rational design of immunotherapeutic agents has advanced with a funda-
mental understanding that both innate and adaptive immunity play important roles 
in cancer surveillance and tumor destruction; given that oncogenesis occurs and 
cancer progresses through the growth of tumor cells with low immunogenicity in an 
increasingly immunosuppressive tumor microenvironment. Checkpoint inhibitors in 
the form of monoclonal antibodies that block cancer’s ability to deactivate and evade 
the immune system have been widely indicated for a variety of tumor types. Through 
targeting the biological mechanisms and pathways that cancer cells use to interact 
with and suppress the immune system, immunotherapeutic agents have achieved 
success in inhibiting tumor growth while eliciting lesser toxicities, compared to 
treatments with standard chemotherapy. Development of “precise” bio-active 
tumor-targeted gene vectors, biotechnologies, and reagents has also advanced. This 
chapter presents ongoing clinical research involving immune checkpoint inhibitors, 
while addressing the clinical potential for tumor-targeted gene blockade in combina-
tion with tumor-targeted cytokine delivery, in patients with advanced metastatic 
disease, providing strategic clinical approaches to precision cancer immunotherapy.
Keywords: PD-1 inhibitor, CTLA4 inhibitor, DeltaRex-G, DeltaVax, NK cells, 
checkpoint inhibitors, cell cycle control, GMCSF
1. Introduction
The human immune system is an intricate network of cell types and signaling 
pathways that act in a concerted effort to ensure that when an immune response 
is elicited, it is directly proportional to the severity of the attack. Although this 
network exists to protect the body from foreign invasion, an overactive immune 
response can lead to immunopathogenesis and autoimmunity, thus it is crucial that 
there are mechanisms set in place to ensure this system remains tightly regulated 
[1]. The immune system achieves this strict regulation by engaging a complex 
system of checkpoint control pathways. These checkpoints act as metaphorical 
gateways that require a specific key, in the form of a protein or a small molecule, in 
order to initiate tightly regulated signaling pathways that prevent over-reactivity 
of an immune response through the binding of specific cell surface receptors. 
This process is known as peripheral tolerance [2]. Certain checkpoint pathways, 
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including those involving transmembrane protein receptors cytotoxic t-lymphocyte 
antigen 4 (CTLA-4) and programmed death 1 (PD-1), play pivotal inhibitory roles 
in T-cell activation. Specifically, the CTLA-4 checkpoint is designed to inhibit 
T-cells from becoming autoreactive during the beginning stages of T-cell activation, 
while the PD-1 checkpoint is part of a family of costimulatory receptors that, when 
bound to its ligand, inhibits T-cell proliferation [2].
Tumor cells exploit the process of peripheral tolerance as a way to evade 
immunological surveillance by mimicking inhibitory receptors that are normally 
expressed on the surface of antigen presenting cells [3]. Expressing these inhibitory 
receptors allows cancer cells to effectively downregulate an immune response by 
deactivating the T-cells they come into contact with. The development of genetically 
engineered immune checkpoint inhibitors (ICIs) to treat malignancies therefore has 
the potential to revive pre-existing immune responses that would have otherwise 
been suppressed by the cancer [4]. Immunotherapies have been developed over 
the past decade using monoclonal antibodies as checkpoint inhibitors, binding the 
inhibitory receptor on T-cells and blocking tumor cells from binding to these sites.
The first immune checkpoint inhibition therapies to enter clinical trials for 
patients with advanced cancer were two fully human CTLA-4 blocking antibodies, 
ipilimumab and tremelimumab. Clinical activity of the CTLA-4 blockade was most 
significant in advanced melanoma patients, leading to a 15% response rate that, 
for some patients, persisted for over 10 years after discontinuing therapy [5]. In 
2010, a large Phase III trial was published showing ipilimumab to have significantly 
improved overall survival rates in patients with metastatic melanoma, compared 
to treatment with standard gp100, a synthetic peptide cancer vaccine, alone [6]. 
Ipilimumab has since been FDA approved in combination for the treatment of 
advanced renal cell carcinoma, microsatellite instability high (MSI-H) or mismatch 
repair deficient (dMMR) metastatic colorectal cancer, hepatocellular carcinoma, 
non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma.
The PD-1 checkpoint pathway was the next to be targeted with antibody therapy. 
Similar to ipilimumab, the first nivolumab trials were also shown to be most effica-
cious in melanoma patients, although it is now approved not only for the treatment 
of melanoma, but also of non-small cell lung cancer (NSCLC), small cell lung 
cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, 
squamous cell carcinoma of the head and neck, urothelial carcinoma, MSI-H or 
dMMR metastatic colorectal cancer, hepatocellular carcinoma, and esophageal 
squamous cell carcinoma. A study assessing the efficacy of anti-CTLA-4 and 
anti-PD-1 combined therapy in melanoma patients showed even more significant 
results, with 53% of patients achieving an objective response, and ≥ 80% tumor 
reduction was reported in all patients [7].
Thus far, the only two immune checkpoint inhibitors that have been successfully 
brought to market are those that involve the PD-1/PD-L1 checkpoint and CTLA-4 
checkpoint. These targets are within the adaptive immune system, but scientists are 
looking at the potential anti-tumor effects of exploring checkpoint targets within 
the innate immune system. Another target currently being investigated involves 
immune checkpoint inhibition within natural killer (NK) cell-mediated immunity. 
Cancer cells frequently downregulate their MHC expression, rendering T-cell medi-
ated immunotherapy insufficient for killing these tumor cells. NK cell-mediated 
treatment can, in theory, compensate for this. As a first line of defense within the 
immune surveillance system, NK cells are quicker to become activated and will 
indiscriminately induce apoptosis in any cell lacking MHC-receptors.
Similar to the immune system, a checkpoint control system is also used to control 
the distinct phases of the cell division cycle in order to regulate cellular proliferation. 
Unrestrained cell division is a fundamental characteristic of oncogenesis, therefore 
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cell cycle checkpoint control is vital in preventing the development of cancer. The 
mechanism of action in this case of checkpoint control is site-specific protein phos-
phorylation executed largely by cyclin-dependent proline-directed protein kinases. 
For example, Cyclin D1 and CDK4/6 are downstream of growth-initiating signaling 
pathways which lead to cellular proliferation. Palbociclib, an inhibitor of cyclin-
dependent kinases CDK4/CDK6 is approved for the treatment of HR-positive, 
HER2-negative advanced or metastatic breast cancer in combination with an 
aromatase inhibitor as initial endocrine based therapy in postmenopausal women or 
fulvestrant in women with disease progression following endocrine therapy [8].
Another example of an executive cell cycle regulatory protein is the cyclin G1 
protein, product of the CCNG1 proto-oncogene: (i) identified as the prime molecu-
lar driver of “Cell Competence” (to proliferate), (ii) needed for quiescent cells to 
enter the G1 phase, subject to oncogene-addiction as a molecular survival factor [9]. 
Tumor-targeted gene therapy involving CCNG1 blockade was tested in a number 
of clinical trials over a decade ago, and has recently been revived for clinical use, 
upon analysis of long-term cancer-free survival data, as the first clinically validated 
tumor-targeted gene therapy vector of this kind. This genetic medicine, known as 
DeltaRex-G (Former names: Mx-dnG1, dnG1, Rexin-G), is a “retroviral expression 
vector displaying a cryptic/designer collagen-binding motif on its gp70 surface 
envelope, designed specifically for targeting abnormal (anaplastic) Signature (SIG) 
proteins in the tumor microenvironment and encoding a dominant-negative mutant 
construct (dnG1) of human CCNG1 (Cyclin G1)oncogene/survival factor [10]. 
Once administered intravenously, the DeltaRex-G nanoparticles (~100 nm) accu-
mulate in cancerous lesions, where the transgene is expressed, using the tumor cell’s 
replication machinery to translate a mutant, cytocidal protein that is specifically 
designed to block the Cyclin G1 pathways of cell competence and survival function, 
leading to active cancer cell death via apoptosis.
Herein, we discuss the current landscape of immune and cell cycle checkpoint 
inhibition by presenting a selected number of ongoing and past clinical research 
for advanced malignancies at the Cancer Center of Southern California (CCSC)/
Sarcoma Oncology Research Center (SORC) in Santa Monica, California, in context 
and collaboration.
2. Ongoing clinical research
Ongoing clinical research is either investigator-initiated or company sponsored. 
In the case of investigator-initiated research, CCSC/SORC serves as the spon-
sor, conceives and designs the clinical protocol, and manages the entire clinical 
trial with or without funding by a pharmaceutical company, the FDA or the NIH. 
Company-sponsored research is developed, monitored, and funded by a pharma-
ceutical company.
2.1 Investigator initiated research
2.1.1  SAINT: An Expanded Phase II Study Using Safe Amounts of Ipilimumab, 
Nivolumab, and Trabectedin as First-Line Treatment of Advanced Soft 
Tissue Sarcoma (NCT03138161). Erlinda M. Gordon, Principal Investigator
2.1.1.1 Background & rationale
Soft tissue sarcomas comprise a rare, heterogenous category of malignan-
cies originating from connective tissue, blood vessels or lymphatic tissue [11]. 
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This group accounts for only 1% of adult cancers in the United States, but it has a 
higher mortality rate than testicular cancer, thyroid cancer, and Hodgkin lymphoma 
combined [12]. The most commonly used modalities of treatment for sarcoma have 
been surgery, radiation and chemotherapy. Currently, chemotherapy treatment 
options have been shown to slow down disease progression but are ineffective in 
keeping most patients from eventually developing recurrent and metastatic disease 
[13]. Once unresectable or metastatic, the majority of soft tissue sarcomas remain 
incurable with chemotherapy. Immune checkpoint blockades do not act directly 
on the cancer cell, thus they can theoretically be applied to the treatment of any 
type of solid tumor, including the rarest and most aggressive malignancies. The 
precedent set by the approval of immune checkpoint inhibition for the treatment 
of numerous cancer types provides a strong rationale for studying their effects on 
soft tissue sarcoma. Studies with ipilimumab and nivolumab have since been done 
showing promising results when used in patients with advanced soft tissue sarcoma 
[14]. The third drug in this trial is a marine-derived alkaloid, trabectedin, an FDA 
approved chemotherapy treatment for leiomyosarcoma and liposarcoma [15]. A 
recently published retroactive analysis of 442 patients treated with trabectedin over 
a 10 year period confirms that trabectedin can prolong progression free survival 
(PFS) in patients with advanced sarcoma [16].
Gordon et al. designed the SAINT protocol based on the fact that sarcoma cells 
are most immunogenic early in the disease process [17] and prior to any other 
treatment, allowing immune checkpoint inhibitors to exploit this advantage and 
deploy the immune system to recognize and destroy them. This study was designed 
to evaluate the best objective response rates (BORR) assessed via CT scan or MRI 
and to assess the overall survival (OS) and progression-free survival (PFS) after 
6 months of treatment.
2.1.1.2 Methods
Eligible patients for this Phase II clinical trial were treatment-naïve adult 
patients with advanced unresectable or metastatic soft tissue sarcoma. Trabectedin 
was administered to the study subjects at the maximum tolerated dose determined 
previously in the dose escalation phase of this trial. Ipilimumab and nivolumab were 
be administered at defined doses in order to assess the overall safety profile and 
potential efficacy of this treatment regimen. Patients continued on the treatment 
until they experienced significant disease progression or unmanageable toxicities. 
Best objective response was measured according to Response Evaluation Criteria 
in Solid Tumors (RECIST) v1.1 using CT scan or MRI. Median progression-free 
survival (PFS) and overall survival (OS) were also measured in months. Adverse 
events were assessed and categorized as related or unrelated to the treatment and 
listed by severity according to the Common Terminology Criteria for Adverse 
Events (CTCAE) version 5.0.
2.1.1.3  Preliminary results were presented at the Connective Tissue Oncology 
Society Meetings, November, 2020
Sixty subjects were evaluated using RECIST v1.1 for analysis of treatment effi-
cacy. Twenty-five percent (25%) had either a complete response (11.7%) or a partial 
response (13.3%), and 37 patients (61.7%) had stable disease. Disease control rate 
was 86.6%. The median PFS was >6.7 months (6-month OS rate: 90%; 6-month PFS 
rate: 51%), while the median OS was >17.0 months.
Grade 3 TRAEs included fatigue (n = 6), adrenal insufficiency (n = 1), hypergly-
cemia (n = 1), dehydration (n = 1), hyponatremia (n = 2), bipedal edema (n = 2), 
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increased AST (n = 6), increased ALT (n = 19), increased ALP (n = 1), port site 
infection (n = 2), psoriasis exacerbation (n = 1), anemia (n = 3), thrombocytope-
nia (n = 2), leukopenia (n = 1), and neutropenia (n = 3). Grade 4 TRAES include 
anemia (n = 1), neutropenia (n = 1), thrombocytopenia (n = 1), and increased 
CPK (n = 2). Grade 5 TRAES include rhabdomyolysis (n = 1). Therapy related AML 
occurred in one patient.
2.1.1.4 Conclusions/future directions
The positive results from this trial thus far strongly suggest that using combina-
tion therapy with ipilimumab, nivolumab, and trabectedin as first-line treatment 
in patients with advanced or metastatic sarcoma allows the treatments to engage 
synergistically without causing any additive toxicities. This combination may 
be superior to known therapies for STS. Overall, the adverse events experienced 
less severe than toxicities typically experienced with standard first line treat-
ment (doxorubicin/ifosfamide) for metastatic soft tissue sarcoma. Future Phase 
3 randomized studies are proposed to evaluate the safety and efficacy of first-line 
combinatorial therapy with ipilimumab, nivolumab and trabectedin in comparison 
to standard therapy for patients with advanced soft tissue sarcomas.
2.1.2  The TNT Protocol: A Phase II Study Using Talimogene Laherparepvec, 
Nivolumab, and Trabectedin as First, Second/Third Line Therapy 
for Advanced Sarcoma, including Desmoid Tumor and Chordoma 
(NCT03886311). Sant P. Chawla and Erlinda M. Gordon, co-Principal 
Investigators
2.1.2.1 Background & rationale
The significant immunotherapeutic potential of oncolytic virotherapy is due to 
its ability to induce a multifaceted anti-tumor response involving aspects of both 
the innate and adaptive immune systems [18]. A multitude of viral vectors have 
been explored for their potential oncolytic properties, particularly as a method 
of delivering targeted treatment to sites of malignant disease [19]. The ability to 
genetically modify these viruses to target and exploit essential oncogenic signal-
ing pathways has kept them at the forefront of immuno-oncology research [20]. 
This particular vulnerability triggers selective replication of the viral genome and 
directly contributes to furthering the oncolytic process. Infected tumor cells secrete 
viral progeny composed in part by tumor-associated antigens and neoantigens in 
response to their infection, causing the innate immune system to activate an NK 
cell-mediated cytotoxic response. The tumor-associated antigens that are released 
into the tumor microenvironment are phagocytosed by antigen-presenting cells, 
thus initiating the process of T-cell-mediated adaptive anti-tumor immunity. In 
addition to the anti-tumor response, the presence of the oncolytic virus also triggers 
a concurrent anti-viral response, and regulatory mechanisms become crucial to 
ensuring a controlled immune response, including the upregulation of immune 
checkpoints [20].
Oncolytic viruses derived from Herpes simplex virus 1 (HSV-1) vectors are 
amongst the most frequently investigated in pre-clinical trials and have been shown 
to encompass the combined ability to induce oncolysis and anti-tumor immune 
responses simultaneously [21]. Talimogene Laherparepvec (T-VEC) is an inject-
able live, attenuated, oncolytic HSV-1 virus that has been genetically engineered to 
express human granulocyte-macrophage colony-stimulating factor (huGM-CSF), 
a known immune modulator and hematopoietic growth factor that stimulates the 
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differentiation of multipotent progenitor cells and plays a key role in the functional 
abilities of many different circulating lymphocytes, including T-cells [22].
The objective of this ongoing study is to evaluate the potentially synergistic 
effects T-VEC may evoke when used in combination with anti-PD-L1 monoclonal 
antibody, nivolumab and marine derived alkaloid, trabectedin. The study is ongoing.
2.1.2.2 Methods
This open-label Phase II study is designed to assess the safety and efficacy of 
this combination treatment. This will be accomplished by determining the median 
month of progression-free survival, median duration of response, and best overall 
response rates based on each patients’ percent of change in their tumor sizes. This 
study plans to enroll 40 participants with advanced disease who have at least one 
tumor that is easily accessible for intratumoral injection with T-VEC. Regarding the 
statistical analysis, continuous variables will be summarized by the sample size (n) 
and measures of central tendency and variation will be calculated including mean, 
standard deviation, first and third quartiles, maximum and minimum. Categorical 
variables will be summarized by the sample and by the percent in each category. 
“Point estimates for efficacy endpoint incidences will be accompanied by a 2-sided 
95% exact binomial CI. Time to event endpoints will be summarized descriptively 
using the KM method. Safety (incidence and severity of adverse events and signifi-
cant laboratory abnormalities) will be performed on all patients (ITT population). 
Patient incidence of all treatment emergent AEs will be tabulated by system organ 
class and preferred term” [23].
2.1.2.3  Preliminary results presented at the Connective Tissue Oncology Society 
meetings, November, 2020
Efficacy analysis (n = 31): There were 6.5% partial responses, 80.6% disease 
control rate, with 74.1% PFS rate and 92.6% OS rate at 4 months.
Safety Analysis (n = 41): Grade 3 TRAEs include fatigue (n = 2), decreased 
ejection fraction (n = 1), anasarca (n = 1), dehydration (n = 1), decreased cortisol 
(n = 1), anemia (n = 9), thrombocytopenia (n = 4), neutropenia (n = 4), gastroen-
teritis (n = 1), increased ALT (n = 8), increased AST (n = 1), and increased GGT 
(n = 1). Grade 4 TRAEs observed were thrombocytopenia (n = 2). There was no 
conversion from unresectable to resectable tumor. There were thirty-one evaluable 
subjects for efficacy analysis.
2.1.2.4 Conclusions/future directions
Second- or third- line combinatorial therapy with talimogene laherparepvec, 
nivolumab, and trabectedin.
1. may be equal or better than standard second/third line therapy in achieving 
disease control.
2. may be safer than standard therapy for patients with advanced soft tissue sar-
coma with no unexpected toxicities.
2.1.2.4.1 Future directions for research
Studies are proposed to evaluate the efficacy and safety of first, second/
third line combinatorial therapy with talimogene laherparepvec, nivolumab and 
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trabectedin vs. standard therapy (doxorubicin/ifosfamide) in randomized studies 
for advanced soft tissue sarcomas.
2.1.3  A Phase Ib investigation of safety/efficacy of nivolumab and ABI-009 (nab-
rapamycin) in advanced undifferentiated pleomorphic sarcoma (UPS), 
liposarcoma (LPS), chondrosarcoma (CS), osteosarcoma (OS) and Ewing 
sarcoma (NCT03190174). Erlinda M. Gordon, Principal Investigator
2.1.3.1 Background & rationale
Aberrant mTOR signaling, typically due to either an activating mutation in onco-
genes related to the mTOR pathway or a loss of function mutation in an upstream 
tumor suppressor gene, has been found to play a significant, multifaceted role in 
oncogenesis [24, 25]. Originally discovered while investigating the targets of the drug 
rapamycin, a potent immunosuppressive agent, in the early 1990’s, the protein kinase, 
mammalian target of rapamycin (mTOR), is a major signaling hub for directing 
cellular growth, metabolism, and proliferation [26]. While studying the mechanism 
of action behind rapamycin’s inhibitory effects on mTOR signaling, the drug was also 
found to be involved in the inhibition of T-cell proliferation, specifically between the 
G1 and S phases of the cell cycle. This finding launched a multitude of studies to better 
understand the role of mTOR signaling in T-cell activation and proliferation [27], cul-
minating in the discovery that T-cells are also highly dependent on mTOR signaling to 
maintain normal T-cell activation and proliferation [28]. When t-cells receive immune 
stimuli, they then rely on signals from mTOR to promote t-helper cell differentiation 
while simultaneously inhibiting the induction of regulatory T-cells. Thus, mTOR 
exerts control over essential regulatory signals in both adaptive and innate immunity.
Initial clinical studies investigating the anti-cancer effects of single agent 
mTOR inhibitor, were disappointing, reporting its limited effects, thus leading to 
the investigation of rapamycin in combination with various chemotherapy agents 
where it was successful in inhibiting cancer growth in prostate cancer patients 
[29]. However, the experimental drug, ABI-009 or nab-sirolimus, a novel albumin-
bound mTOR inhibitor, has been shown to be effective and safe for the treatment of 
malignant perivascular epithelioid cell tumors (PEComa) [30]. A phase 1/2 trial is 
currently ongoing to investigate the potential synergistic activity of nab-sirolimus 
when administered with an immune checkpoint inhibitor, nivolumab, in improving 
clinical outcomes for patients with advanced sarcoma.
2.1.3.2 Methods
The original objectives of the study are: (1) To investigate the maximum toler-
ated dose (MTD) of ABI-009 when given with nivolumab, a PD-1 inhibitor, in 
previously treated advanced undifferentiated pleomorphic sarcoma, liposarcoma, 
chondrosarcoma, osteosarcoma and Ewing sarcoma; (2) To investigate the disease 
control rate (DCR), progression-free survival (PFS), and overall survival (OS) of 
this combination therapy in the aforementioned patient group, and (3) To correlate 
PFS with PD-L1 and other biomarker expression in patients’ tumors.
This is an IRB approved protocol with 2 parts. The phase 1 part is a dose-finding 
study using the “cohort of three design”, wherein a standard dose of nivolumab 
240 mg is given IV every 3 weeks (day 1 of every 21-day cycle). Escalating doses of 
ABI-009 are given IV on days 8 and 15 of each cycle starting in Cycle 2 following the 
2nd nivolumab dose. The starting dose of ABI-009 is 56 mg/m2, and sequentially 
escalating doses are 75, and 100 mg/m2. Phase 2 of the study will enroll 31 addi-
tional patients to further assess efficacy and safety at the MTD.
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2.1.3.3 Preliminary results presented at the ASCO annual meeting in June, 2019
The Phase I part of study included 9 patients who were treated successfully at 
3 dose levels. No dose-limiting toxicities (DLTs) were observed, the MTD was not 
reached, and 100 mg/m2 ABI-009 was designated as the recommended Phase II 
dose. Safety analysis: At Dose 1 (n = 3): Grade 3 treatment-related adverse events 
(TRAEs) included dyslipidemia (n = 1) and hyperglycemia (n = 1). At Dose 2 
(n = 3): Grade 3 TRAEs included increased ALT (n = 1). At Dose 3 (n = 3): Grade 3 
TRAEs included hypophosphatemia (n = 1).
2.1.3.4 Conclusions/future directions
The primary endpoint has been met with no DLTs, the MTD was not reached 
and Dose 3 (100 mg/m2) of ABI-009 has been designated as the phase 2 dose which 
is on-going.
2.2 Company sponsored clinical research
2.2.1  Phase I Study of INBRX-109 in Subjects With Locally Advanced or 
Metastatic Solid Tumors Including Sarcomas (NCT03715933) Sant P. 
Chawla, Principal Investigator
2.2.1.1 Background & rationale
The initiation of the extrinsic apoptosis pathway is mediated by several death 
domain receptors including death receptor 5 (DR5), a transmembrane protein 
receptor activated by the tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) [31]. The DR5 apoptosis pathway naturally occurs to rid the body of 
neoplastic cells and is known to be crucial in immune system surveillance against 
cancer growth and metastasis. Normally, when an anchorage-dependent cell 
becomes detached, the cell will undergo a process of detachment-induced apoptosis 
called anoikis, initiated by a death receptor-mediated apoptotic pathway. A reduc-
tion in DR5 expression was found in melanoma tumor samples, strongly implying 
the TRAIL/DR5 pathway is associated with the prevention of tumor metastasis [32]. 
In 1999, Walczak et al. observed tumor cells to have a significantly higher sensitivity 
to TRAIL than normal cells, emphasizing its potential as a therapeutic cancer agent 
[33]. The subsequent development of agonistic antibodies against DR5 (i.e. recom-
binant human TRAIL proteins) was shown to be successful in stimulating apoptosis 
when tested in various tumor cell lines, and was later also shown to enhance the 
efficacy of chemotherapy and radiotherapy [34].
INBRX-109 is a tetravalent DR5 agonist antibody designed to initiate the DR5 
apoptosis pathway and precisely engineered to avoid unnecessary crosslinking to 
lower the risk of hepatotoxicity.
2.2.1.2 Methods
This is the first in-human, open-label, non-randomized Phase I clinical trial for 
INBRX-109. Eligible patients had metastatic or unresectable solid tumors refractory 
to standard treatment or for which there is no FDA approved standard treatment. 
Phase I consists of two parts, part 1 being a 3 + 3 dose escalation cohort and part 2 
being a dose expansion cohort. Safety, tolerability and dose-limiting toxicity were 
measured and analyzed using the National Cancer Institute’s Common Terminology 
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Criteria for Adverse Events (CTCAE) criteria to assess the severity of adverse events 
experienced. This study’s exploratory objective is an assessment of anti-tumor 
activity and was reported according to RECIST v1.1 standard.
2.2.1.3 Preliminary results presented at the CTOS meeting, November, 2020
Overall, INBRX-109 was well tolerated and approximately 90% of patients 
showed no signs of hepatotoxicity. The pharmacokinetics of INBRX-109 were 
approximately dose proportional across all doses tested and thus support dosing 
every 3 weeks without administration of any premedications. All patients have 
thus far tested negative for anti-drug antibodies. Maximum tolerated dose was 
not reached in the dose escalation cohort and only one dose-limiting toxicity was 
experienced. Very few serious adverse events that occurred were attributable to 
the drug being studied. One patient with mesothelioma has been reported to have 
experienced acute hepatic failure leading to death that could possibly be related 
to the study drug. Evidence of anti-cancer effects were observed in patients with 
chondrosarcoma, resulting in durable partial responses and stable disease.
2.2.1.4 Conclusions/future directions
NBRX-109, a precisely engineered tetravalent DR5 agonist antibody, showed 
promising results that warrant further exploration. The pharmacokinetics of 
INBRX-109 were essentially dose-proportional across all three dose levels, support-
ing dosing every three weeks with no premedications necessary. Specifically, the 
chondrosarcoma cohort of this Phase I study has been expanded to include twenty 
patients and is currently ongoing.
2.2.2  An Open-labeled, Phase I Study to Evaluate the Safety and Tolerability 
of Apatinib with Nivolumab in Patients with Unresectable or Metastatic 
Cancer (NCT03396211) Sant P. Chawla, Principal Investigator
2.2.2.1 Background & rationale
Unregulated angiogenesis is one of the key characteristics of malignant tumors 
[35]. In addition to creating neovasculature, tumor angiogenesis plays a key role in 
creating an immunosuppressive tumor microenvironment by causing an accumula-
tion of pro-tumor immune cells and a decrease in the abundance and function of 
anti-tumor immune cells. Anti-angiogenic cancer treatments have been shown to 
reverse this process, essentially ‘reprogramming’ the tumor microenvironment 
by converting it from an immunosuppressive to an immunogenic one. This has 
been accomplished by targeting and inhibiting vascular endothelial growth factor 
(VEGF), a well-known cell surface-signaling proangiogenic protein that becomes 
stimulated when bound to tyrosine kinase receptors. With the use of antiangiogenic 
small molecule tyrosine kinase inhibitors (TKIs), VEGF can be blocked from bind-
ing its receptor, stopping the tumor from being able to continue to create neovas-
culature [36]. However, cancer has been able to circumvent this blockade using 
multiple other pathways, suggesting the use of antiangiogenic therapies that inhibit 
more than one signaling pathway simultaneously.
The experimental drug, apatinib, is a highly selective VEGFR-2 TKI, admin-
istered orally, that has already been approved in China for ≥3rd-line treatment 
for advanced gastric cancer. The potential benefit of combining TKI and PD-1 
therapies has been demonstrated in preclinical murine models, suggesting that 
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combining ICIs with antiangiogenesis therapy could have the synergistic antitumor 
effects needed to enhance the efficacy of the individual therapies [37]. This phase 1 
single-center clinical trial beginning in 2018 evaluated the safety and tolerability 
of TKI, apatinib, and PD-1 inhibitor, nivolumab, in patients with unresectable or 
metastatic cancer.
2.2.2.2 Methods
All subjects enrolled had cancer that was refractory to prior lines of treatment. 
Specifically, patients were required to already be at least three cycles into nivolumab 
treatment and must be planning to continue this treatment throughout the trial 
period. Thirty patients in total were enrolled, ten of which were in part 1 of this 
study, where they were treated with apatinib using a classic 3 + 3 dose escalation 
method in order to determine the maximum tolerated dose. Part 2 of this study 
included twenty subjects and was an expansion phase using the MTD. The percent 
of change in tumor responses and amount of time until progression were measured 
and analyzed using RECIST v1.1 and iRECIST criteria.
2.2.2.3  Preliminary results presented at the Connective Tissue Oncology Society 
meetings, November, 2020
The overall response rate reported was 13.3% (95% CI: 3.8% to 30.7%) 
and the median PFS was 7.2 months (95% CI: 5.3 to 9.0 months). No complete 
responses occurred although four patients achieved a partial response and the 
majority of patients achieved stable disease. Seven patients from part 1 and six 
patients from part 2 experienced ≥ grade 3 treatment emergent adverse events 
including fatigue (10.0%), hypertension (10.0%), nausea (10.0%), anemia 
(16.7%) and asthenia (10.0%). Two patients experienced fatal adverse events, 
although there were no noted treatment related deaths. Nine patients eventually 
discontinued the study due to toxicity, and nine patients also received a dose 
reduction. No unexpected side effects were noted as a result of the combined 
treatment.
2.2.2.4 Conclusions/future directions
The results of this study demonstrate an acceptable safety profile and clini-
cal benefit of combination treatment with nivolumab and apatinib that is worth 
exploring further in additional clinical studies.
2.2.3  Phase 1, Open-Label, Safety Study of Escalating Doses of Ex Vivo Expanded, 
Autologous Natural Killer Cells in Patients With Pathologically Confirmed 
Cancer Refractory to Conventional Therapy (NCT03941262). Sant P. 
Chawla, Principal Investigator
2.2.3.1 Background & rationale
Natural killer (NK) cells are the cytotoxic lymphocytes of the innate immune 
system [38]. As a rapid, first line of defense, NK cells are able to lyse tumor cells 
independent of the expression of tumor-associated antigens and/or the presence of 
major histocompatibility complex class I (MHC-I) molecules. This ability is crucial 
as cancer cells have been shown to downregulate the expression of MHC-I on their 
cell surface as a way to evade detection by immunosurveillance mechanisms [39]. 
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Since the expression of MHC-I on cancer cells is needed for their detection and 
destruction by T-cells, evolving a loss of MHC-I expression has been a way for 
tumor cells to remain undetectable and this loss has therefore been reported “as a 
mechanism of resistance to anti–PD-1 therapy” [40]. In order to avoid the develop-
ment of resistance to PD-1 checkpoint inhibition therapy, exploration of NK cell 
therapy is warranted, especially because of the NK cell’s specific role in the recog-
nition and destruction of cancer cells that display a loss of MHC-I. Additionally, 
the broad ability of NK cells to destroy tumor cells irrespective of prior sensitiza-
tion or immunization therapy make them ideal candidates for engineered cell 
therapies.
Discoveries regarding the NK cell’s role in anti-tumor immunity coupled with 
advancements in the field of hematopoietic stem cell transplantation have brought 
to light the potential in using NK cell-mediated immunotherapeutic strategies to 
fight cancer [41]. Adoptive immunotherapy using donor-derived autologous NK 
cell products can be engineered by using monoclonal antibodies alone, or in com-
bination with in vivo and ex vivo NK cell activation techniques [42]. This is done 
by obtaining a patient’s NK cells and incubating them as highly active NK cells, 
giving them the ability to mass produce NK cells which are then infused back into 
the patient. This study explores the safety and tolerability of treating cancer with 
SNK01 (autologous natural killer cells).
2.2.3.2 Methods
This study is a nonrandomized, multicenter safety study of adoptively infused, 
ex vivo expanded autologous NK cells to treat male and female adult patients with 
advanced or metastatic, intractable cancer. Study subjects were placed in one of 
three cohorts and received SNK01 in an open-label fashion according to a 3 + 3 
Phase 1 dose-escalation method. Patients received 5 weekly infusions for a period 
of 5 weeks, and restaging imaging was performed on week 6. The primary objec-
tive of this study was a safety assessment based on the incidence and severity of 
dose-limiting toxicities and other adverse events observed by evaluating vital signs, 
clinical laboratory findings and physical examination abnormalities. The adverse 
events were graded according to the CTCAE v5.0 criteria. Subjects’ performance 
status was assessed and recorded using ECOG criteria. The secondary objective is to 
evaluate the efficacy of the treatment by measuring the objective response rate of 




In order to effectively achieve immune surveillance, immunosuppressive signals 
within the tumor microenvironment must be interrupted. The PD-1/PD-L1 signal-
ing blockade was developed in accordance with this principle. Tumors have been 
shown to secrete cytokines associated with suppression of T-cells and NK cells, and 
past murine studies have shown circulating IL-18 in low levels originating from 
tumor cells can suppress NK anti-tumor activity [41]. The principles of checkpoint 
blockade can be applied here with the development of a neutralizing antibody to 
IL-18, suggesting the potential of checkpoint inhibition to improve in vivo NK cell 
activity.
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3. Past clinical research
3.1  Immune Design: A Randomized, Open-Label, Phase II Trial of CMB305 
(Sequentially Administered LV305 [lentiviral vector expressing NYESO-1 
gene] and G305[NY-ESO-1 recombinant protein plus GLA-SE]) and 
Atezolizumab in Patients with Locally Advanced, Relapsed, or Metastatic 
Sarcoma Expressing NY-ESO-1 (NCT02609984) Sant P. Chawla, Principal 
Investigator
3.1.1 Background & rationale
NY-ESO-1 is a protein that is normally expressed in fetal and testicular tis-
sues, although some solid malignancies have been known to express an abnormal 
NY-ESO-1 protein that has become a target for emerging antigen-directed cancer 
therapies [43, 44]. Previous studies looking at NY-ESO-1 expression in cancer cells 
have reported its presence in the majority of synovial sarcomas tested, as well as 
sporadic expression in a number of other sarcoma subsets [45]. The immunoge-
nicity of NY-ESO-1 has been demonstrated by the discovery of receptors against 
NY-ESO-1 on CD8+ T-cells. A 2011 clinical trial conducted by the National Cancer 
Institute was the first to report promising anticancer effects of NY-ESO-1-targeted 
immunotherapy in patients with metastatic synovial sarcoma using adoptively 
transferred autologous T-cells containing a T-cell receptor against NY-ESO-1 [46], 
suggesting its potential to be effective in other sarcomas as well. Since then, numer-
ous trials targeting NY-ESO-1 in various cancer types using both adoptive T-cell 
therapy and vaccination approaches have concluded that there is a clear clinical 
benefit in pursuing NY-ESO-1 as an immunotherapeutic target [47].
The drug being studied is CMB305, a prime-boost immunotherapeutic vac-
cine regimen developed to prime the immune system and enhance its subsequent 
response to immunotherapeutic agents. The priming component of CMB305 is an 
integration-deficient, replication-incompetent lentiviral vector containing RNA 
coding for NY-ESO-1. The boost component contains a recombinant E. coli-pro-
duced NY-ESO-1 protein that, as a single agent, can initiate anti-NY-ESO-1-specific 
CD4+ T-cell and antibody responses. The combination of the primer and the booster 
was designed with the intention of eliciting an enhanced T-cell response.
The goal of this study was to investigate the ability of a prime-boost immuno-
therapy regimen that is able to elicit NY-ESO-1-specific CD8+ T-cells to synergisti-
cally enhance the efficacy of PD-L1 checkpoint inhibition therapy in advanced or 
metastatic sarcoma patients whose tumors are positive for NY-ESO-1 expression.
3.1.2 Methods
The primary objective of this study was to compare the progression-free sur-
vival in locally advanced or metastatic sarcoma patients whose tumors expressed 
NY-ESO-1 when treated with CMB305 in combination with atezolizumab versus 
patients treated with atezolizumab alone. The secondary objectives of this study 
were to evaluate the safety of this combination treatment, as well as to evaluate 
the best overall response rate using RECIST v1.1 modified to use immune-related 
response criteria. The overall survival of the two groups will be evaluated.
Twelve patients were randomized 1:1 in a safety run-in evaluation. Next, 
80 patients were randomized and stratified by disease. Tumor samples from all 
patients were tested for levels of PD-L1 and NY-ESO-1 expression prior to treat-
ment, and again on Day 42 in order to assess the extent of successful immune 
cell invasion in the tumor. Re-staging imaging studies were performed every six 
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weeks for the first twelve months, followed by staging every twelve weeks until the 
patient displayed symptomatic progression. CMB305 treatment was administered 
in seven doses over a three-month period, while atezolizumab was administered 
intravenously every three weeks, and was continued up to two years or until toxici-
ties began to develop. An additional booster dose was also given every six weeks 
for the first year or until the patient displayed disease progression. Blood samples 
were collected to test for lentivirus vector persistence at baseline, six, twelve and 
twenty-four months following the initial treatment. Adverse events were recorded 




Phase I of this trial was the first of its kind to test a prime-boost vaccination 
regimen to treat patients with advanced cancer. In 2018, Immune Design released 
information stating that an early analysis of the Phase II clinical trial results showed 
the combination treatment of atezolizumab with CMB305 suggested that it is 
unlikely this regimen will show enhanced survival time of patients with recurrent 
synovial sarcoma [48]. A Phase III trial has not yet been pursued.
3.2  A Phase I-II Study Using DeltaRex-G (Former name:Rexin-G)Tumor-
Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor 
for Advanced Pancreatic Cancer (NCT00504998) Sant P. Chawla, Michael 
Morse, Howard Bruckner, Principal Investigators
3.2.1 Background & rationale
Advanced pancreatic adenocarcinoma is the third most common cancer type 
in the Unites States, although diagnostic tests are non-specific which leads to 
early-stage disease frequently going undetected [49, 50]. Once pancreatic adeno-
carcinoma reaches an advanced stage, it has likely become intractable and there is 
no cure. Previous targeted therapies revolved around the epidermal growth factor 
receptor (EGFR) signaling pathway, one of the most significant factors regulating 
cell growth, survival, differentiation and proliferation, making it a promising target 
for precision medicine [51]. EGFR signaling has been identified as an oncogenic 
driver in multiple cancer types, and EGFR inhibitors have been used as targeted 
therapy for pancreatic cancer [52].
DeltaRex-G is the first injectable tumor-targeted gene delivery system to be 
developed for cancer that blocks the G1 checkpoint of the cell division cycle of can-
cer cells by inhibiting the CCNG1 gene. DeltaRex-G includes a mutant construct of 
the CCNG1 gene that inhibits human cyclin G1, a proto-oncogene that promotes cell 
competence, cell survival, and stem cell proliferation. When administered systemi-
cally, DeltaRex-G seeks out and accumulates in tumor tissues by binding abnormal 
collagenous signature (SIG) proteins that are characteristically exposed as anaplasia 
during tumor invasion. Once the DeltaRex-G retrovector is incorporated in rapidly 
dividing cells, a cytocidal CCNG1 inhibitor protein is expressed that effectively 
blocks the cell division cycle, resulting in apoptosis and subsequent eradication of 
cancer cells, proliferative vasculature, and stroma.
Clinical data from DeltaRex-G trials conducted initially in the Philippines 
showed promising results for patients with advanced pancreatic adenocarcinoma. 
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This prompted USFDA Orphan Drug status, leading to progressive clinical trials 
in the United States, using DeltaRex-G to treat chemotherapy-resistant advanced 
pancreatic adenocarcinoma, soft tissue sarcoma, osteosarcoma, and breast cancers. 
This study reports the results compiled from a Phase I-II clinical trial using intrave-
nous infusions of DeltaRex-G as treatment for advanced pancreatic cancer.
3.2.2 Methods
Twenty patients with chemotherapy-resistant metastatic pancreatic cancer were 
enrolled in the trial. Target lesions were identified in each patient and changes in 
tumor size were measured using RECIST v1.0 criteria. Patients were grouped and 
treated at 3 escalating doses of DeltaRex-G, with six patients at Dose 0-I, seven 
patients at dose level II, and seven patients at dose level III. Fifteen patients com-
pleted at least one full 4-week treatment cycle and had a follow-up PET-CT scan. 
These fifteen subjects comprised the modified intent-to-treat (mITT) population 
and were evaluated in terms of their response to the treatment, months of progres-
sion-free survival and months of overall survival.
3.2.3 Published results
The safety analysis revealed no clinically significant dose-limiting toxicities at 
any of the 3 dose levels, with no serious adverse events related to the study drug. 
None of the patients tested positive for vector neutralizing antibodies, replication-
competent retrovirus in peripheral blood lymphocytes, antibodies to gp70, or vec-
tor integration into the genomic DNA of peripheral blood lymphocytes. According 
to the RECIST v1.0 evaluations of tumor responses, one patient achieved a complete 
response, two patients, partial response, and 12 patients, stable disease with 100% 
disease control rate. The median progression free survival by RECIST v1.0 was 
2.7 months, 4.0 months, and 5.6 months at Dose levels I, II, and III, respectively. 
Median overall survival was 4.3 months, 9.2 months, and 9.2 months at Dose levels 
I, II, and III, respectively. A dose response relationship was shown between duration 
of survival and DeltaRex-G dosage (p = 0.03). Consequently, fast track designation 
was given by the USFDA for a planned Phase 2/3 study using DeltaRex-G as second 
line therapy for advanced pancreatic adenocarcinoma.
3.2.4 Conclusions/future directions
DeltaRex-G is a potent cytotoxic cell cycle checkpoint inhibitor. Complete and 
partial responses were observed at dose levels II and III, suggesting a significant 
dose–response relationship between the dose of DeltaRex-G given and the level of 
response seen in the tumors. This relationship is further implied by the increase in 
months of progression free survival as the dosages were increased. Additionally, 
CCNG1 is expressed in over 50% of various different malignancies other than pan-
creatic cancer, suggesting DeltaRex-G’s potential efficacy in other cancer types [10].
3.3  Immune cell trafficking in the tumor microenvironment of human cyclin G1 
(CCNG1) inhibitor-treated tumors
3.3.1 Background & rationale
Cell cycle checkpoint pathways that govern uninhibited cell proliferation can 
be rendered ineffective by a variety of cancer-induced immunosuppressive mecha-
nisms [53]. The experimental cancer gene therapy, DeltaRex-G, is a pathotropic 
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(disease-seeking) retrovector designed to disrupt the cell cycle machinery of 
proliferative tumor cells, forcing them to undergo apoptosis. This is accomplished 
through “precise” tumor-targeted gene delivery to block the Cyclin G1/Cdk/cMyc/
Mdm2/p53 Axis, effectively arresting the dividing tumor cell in G1 phase of the cell 
cycle undermining CCNG1 oncogene addiction. Clinical trials using DeltaRex-G to 
treat cancers that are unresponsive to traditional therapy have shown remarkable 
efficacy in evoking long term cancer-free survival with monotherapy (>10 years) 
in a number of patients with pancreatic cancer, osteosarcoma, soft tissue sarcomas, 
breast cancer, and B-cell lymphoma [54]. Although DeltaRex-G is involved in cell 
cycle checkpoint inhibition, it has also been shown to reduce extracellular matrix 
production by tumor cells and increase immune cell entry into the tumor microen-
vironment, which raises the clinical potential for DeltaRex-G to work synergisti-
cally with specific immune checkpoint inhibitors.
One persistent thought is that blanket recruitment of immune cells to the tumor 
microenvironment may not always be advantageous in creating an effective anti-
tumor response. Certain tumor-infiltrating immune cells of myeloid origin have 
been shown to aid in tumor metastasis [55]. Cancers often progress and metastasize 
using immunosuppressive mechanisms that includes production and secretion of 
molecules that recruit cells involved in immune responses to the tumor microenvi-
ronment, and by exploiting checkpoint altering pathways [56]. Alternatively, and 
plausibly, this is how the innate immune system works in a healthy individual, with 
its molecular start and stop switches to prevent exaggerated immune responses and 
autoimmune disease. This study reviews published literature on the specific tumor-
infiltrating immune cells seen in tumors of patients treated with DeltaRex-G.
3.3.2 Methods
A review of published literature was conducted on articles pertaining to the effi-
cacy of DeltaRex-G in influencing the tumor microenvironment. The tumor types 
identified throughout the literature review included pancreatic adenocarcinoma 
metastatic to the liver, melanoma metastatic to the inguinal lymph node, colorectal 
cancer metastatic to the lungs, pancreatic B-cell lymphoma metastatic to the liver 
and cervical lymph nodes, recurrent breast ductal adenocarcinoma, and non-small 
cell lung carcinoma metastatic to the adrenal gland. The presence of tumor-
infiltrating lymphocytes in excised tumors of patients treated with DeltaRex-G was 
assessed using immunohistochemical staining, and anti-tumor immune cells were 
differentiated from pro-tumor immune cells by their cytological characteristics. 
Agents included in the category of anti-tumor immune cells included dendritic 
cells, helper T-cells, natural killer cells, and killer T-cells. Regulatory T-cells and 
B-cells have the ability to encourage tumor growth by preventing antigen presen-
tation and killer T-cell activation, thus were categorized as possibly pro-tumor 
immune cells. M1 macrophages were categorized as anti-tumor, although M2-type 
tumor-associated macrophages can promote tumor pathogenicity by overpowering 
M1-type tumor-infiltrating macrophages that elicit anti-tumor inflammation and 
were therefore categorized as pro-tumor. Results were reported based on can-
cer type.
3.3.3 Published results
Killer T-cells were identified in the tumor microenvironment of all cancers 
analyzed and helper T-cells were identified in all tumor types except for pancreatic 
B-cell lymphoma metastatic to the liver and cervical lymph nodes. Dendritic cells 
were found in metastatic pancreatic adenocarcinoma, metastatic melanoma, breast 
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ductal adenocarcinoma and metastatic non-small cell lung cancer. Natural killer 
cells were seen in metastatic pancreatic adenocarcinoma and metastatic non-small 
cell lung cancer. M1 macrophages were seen in breast ductal adenocarcinoma.
B-cells, possible pro-tumor cells, were seen in metastatic pancreatic adenocar-
cinoma, metastatic colorectal cancer, breast ductal adenocarcinoma and metastatic 
non-small cell lung cancer. Leukocyte common antigen was seen in metastatic 
pancreatic adenocarcinoma, metastatic melanoma, and non-small cell lung cancer. 
Pro-tumor macrophages were seen in breast ductal carcinoma.
3.3.4 Conclusions/future directions
Activating and optimizing the body’s own immune system is at the core of preci-
sion medicine. Pathologic review showed evidence of enhanced immune cell traf-
ficking in the tumor microenvironment of patients treated with DeltaRex-G, 
suggesting that this treatment activates the innate immune response. This 
implies that DeltaRex-G may enhance the performance of an immunotherapy 
agent when used simultaneously. Three patients identified in the literature with 
metastatic pancreatic cancer, B-cell lymphoma and metastatic osteosarcoma, 
respectively, have survived over 10 years following treatment with DeltaRex-G, no 
cancers have recurred, and no additional treatments have been needed. This clinical 
evidence strongly suggests that DeltaRex-G has the ability to promote cancer 
immunization in situ through CCNG1 inhibition without causing deleterious 
immune suppression [9]. Therefore, further evaluation of the role of DeltaRex-G 
in enhancing immune cell trafficking in the tumor microenvironment is warranted.
3.4  The Genevieve Protocol: Phase I/II Evaluation of a Dual Targeted Approach 
to Cancer Gene Therapy/Immunotherapy. Jorge G. Ignacio, Principal 
Investigator
3.4.1 Background & rationale
Patients whose cancer has recurred or progressed after therapy have likely 
exhausted their treatment options [57]. This is where the need for research towards 
the development of personalized targeted treatments becomes both vital and 
urgent. The GeneVieve (Genes for Life) Protocol was a dose-seeking study for 
chemoresistant solid malignancies and B-cell lymphoma, that evaluated the efficacy 
and safety profile of a dual targeted gene therapy regimen using DeltaRex-G and 
DeltaVax (Former name: Reximmune-C), two personalized vaccination strategies 
aimed to augment immune cell trafficking within the tumor microenvironment 
for in situ autoimmunization. DeltaRex-G is a retrovector encoding a cytocidal 
“dominant-negative” mutant construct of the human CCNG1 (Cyclin G1) onco-
gene. This retrovector is designed to destroy cancer cells, its tumor vasculature 
and tumor associated fibroblasts, expose neoantigens created by the tumor debris, 
inhibit the production of the extracellular matrix and enable immune cells to safely 
enter the tumor microenvironment. DeltaVax is a retrovector encoding the human 
GM-CSF gene, used for evoking T-cell proliferation, dendritic cell maturation and 
polarization of M1 macrophages. United States- and Philippine-based Phase I/II 
studies using DeltaRex-G for sarcoma, pancreatic cancer, and breast cancer led to 
its accelerated approval in the Philippines for all chemoresistant solid malignan-
cies and subsequent USFDA approved Orphan Drug status for pancreatic cancer, 
soft tissue sarcoma and osteosarcoma. In 2009, DeltaRex-G received Fast Track 
designation for a pivotal Phase II/III trial for pancreatic cancer in the United States. 
The GeneVieve protocol added a second retrovector strategically to the DeltaRex-G 
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treatment that encoded a GM-CSF gene to examine the role localized GMCSF might 
play in further improving treatment outcomes and inducing long lasting anti-tumor 
immunity.
3.4.2 Methods
The patient population consisted of 16 adults with unresectable advanced or 
metastatic disease. All subjects had an ECOG score between 0 and 1, adequate 
hematological, kidney and hepatic function, and an estimated survival of 3 months 
or more. A chemistry panel and complete blood count were assessed weekly during 
treatment. DeltaRex-G was administered with escalating doses of DeltaVax, five 
patients at Dose Level I, four patients at Dose Level II, and seven patients at Dose 
Level III. All patients received a minimum of two cycles of treatment over an 
8-week period. Toxicity was assessed prior to each infusion and subsequent treat-
ment cycles using NCI CT-CAE version 3.0 criteria. A staging assessment was per-
formed every 4 weeks with an FDG PET-CT scan. All images were performed and 
reviewed independently by the radiologists and RECIST v1.0 and International PET 
criteria were used to assess overall tumor response and progression-free survival.
3.4.3 Published results
No dose-limiting toxicities were observed at any of the three Dose Levels of 
DeltaVax, and no deaths that occurred were considered to be related to the treat-
ment. None of the patients tested positive for vector neutralizing antibodies, 
replication-competent retrovirus in peripheral blood lymphocytes, antibodies to 
gp70 or vector integration into genomic DNA of peripheral blood lymphocytes. 
Using RECIST v1.0 criteria, three patients achieved a partial response, nine patients 
achieved stable disease, and two patients had progressive disease. The median 
progression free survival was 4.5, 9.0, and 13.0 months for Dose Levels I, II, and III 
respectively, and the median overall survival was 17, 13 and > 21 months for Dose 
Levels I, II, III respectively.
Histopathologic examination of patients’ residual tumor tissues showed vector 
localization as well as GM-CSF transgene expression in necrotic tissue, displaying 
the accuracy in delivery of both treatments. Safety and tolerability are displayed 
by the lack of adverse reactions associated with the study drugs. The one-year 
survival rate of 86% in patients who received higher doses of DeltaVax suggests that 
the combination regimen of DeltaRex-G and Deltavax has significant anti-tumor 
activity in patients with chemoresistant solid malignancies and B-cell lymphoma. In 
addition, the substantial increase in progression free survival with each increased 
dosage of DeltaVax suggests a trend towards a positive dose–response relationship 
between the two treatments.
3.4.4 Conclusions/future directions
DeltaRex-G has displayed through numerous clinical trials its cytocidal 
effect on cancer cells. This effect introduces neoantigens from the tumor into the 
tumor microenvironment to be recognized by the immune system and targeted 
for destruction through T-cell mediation. Nevertheless, these cytotoxic immune 
responses may not be significant enough to overcome the suppressive signals from 
surrounding regulatory T-cells that may also be recruited to the tumor microenvi-
ronment. The addition of DeltaVax is hypothesized to heighten the development of 
dendritic cells and increase proliferation and activation of T-cells, thereby improv-
ing the potency of tumor-targeted DeltaRex-G. These activated T-cells can then go 
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on to recognize and destroy the newly introduced tumor neoantigens. This has the 
potential to further tumor regression and evoke long-lasting antitumor immunity.
This data therefore strongly suggests that the advancement of personalized 
cancer vaccination treatment has the potential to gain control of tumor growth and 
increase overall survival time in patients with advanced or malignant chemoresis-
tant solid malignancies, as well as B-cell lymphomas.
4. Discussion/conclusion/summary
Targeted Immunotherapy has revolutionized the way scientists and physicians 
conceptualize their approaches to cancer treatment and cancer checkpoint controls. 
Mechanistic understanding of innate and adaptive mechanisms of immunity are 
considered important aspects of both physiological cancer surveillance and tumor 
eradication, as seen in immune checkpoint control and in precision blockade of 
cell cycle control elements. The low immunogenicity of cancer cells, as well as the 
tendency of advanced cancers to create an immunosuppressive tumor microenvi-
ronment presents a technical problem of precision tumor-targeted drug delivery 
for both immune checkpoint antibodies and cell cycle control elements, which form 
a rational basis for emerging treatments. The precision of monoclonal antibodies 
as checkpoint inhibitors targeting cancer cells has allowed research to advance in a 
direction that moves away from the untoward toxicities associated with chemother-
apy towards treatments that enhance the naturally powerful cytotoxic responses 
of the immune system. The use of checkpoint inhibitors as cancer immunotherapy 
has been validated in 16 indications; however, immune checkpoint inhibition is still 
only considered appropriate for a specific subset of patients [58], and is often con-
founded by serious immune-related Adverse Events (imAEs). The significance and 
durability of response to treatment with checkpoint inhibitor therapy is generally 
dependent on tumor cells having a high mutational burden or microsatellite insta-
bility that creates an increased amount of neoantigens to be recognized and elimi-
nated by the adaptive immune system [59]. Based on the documented physiological 
tumor-seeking behavior and demonstrated survival value of the tumor-targeted 
gene therapy vectors, DeltaRex-G and DeltaVax, in treating advanced metastatic 
cancers, the successful adaptation of bioactive gene-targeting biotechnologies to 
(i) target FDA-approved off-the shelf checkpoint monoclonal antibodies to tumors, 
and/or (ii) recombinant “tumor-targeted” adaptor proteins have been developed, 
in anticipation of precisely targeting immune checkpoint inhibitors and immunos-
timulatory cytokines against tumors to improve clinical outcomes.
Another strategic approach is enhancing the anti-tumor properties of innate 
immunity. The innate immune system is also regulated by its own activating and 
inhibitory pathways that can be investigated as future targets for NK cell-based 
immunotherapy. One important characteristic to consider when making the case 
for focusing on boosting innate immunity is the fact that innate immune cells play 
a major role in immunosurveillance, acting as the first line of defense. Engaging 
the innate immune system is a necessary prerequisite for antigen-specific T-cells to 
respond, although innate immune cells such as NK cells do not require activation of 
T-cells to kill tumor cells [58]. NK cell activation occurs through their direct interac-
tion with target cells, bypassing the need for antigen presentation and processing. 
Innate immunity is always activated prior to adaptive immunity, however, once 
activated, adaptive immunity has the advantage of higher specificity and lower 
probability of self-harm.
In recent years, the human Cyclin G1 (CCNG1) gene was established as a central 
executive element of a Commanding Cyclin G1/Cdk/Mdm2/p53 Axis: representing 
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a strategic locus for restoring cell cycle checkpoint control through precision gene 
transfer. With the development of the first tumor-targeted cancer gene therapy, 
DeltaRex-G [60], it became possible for patients to (i) benefit clinically, (ii) enjoy 
good quality of life and (iii) survive appreciably longer without experiencing the 
debilitating toxicities of chemotherapy. The tumor-targeted DeltaRex-G vector 
consists of bioactive nanoparticles displaying a high-affinity targeting motif on 
its surface for “pathotropic” (lesion-seeking) targeting by binding to abnormal 
signature (SIG) proteins found abundantly in invading tumors, and then delivering 
a cytocidal genetic payload, a CCNG1 cell cycle checkpoint inhibitor gene, into rap-
idly dividing cancer cells, tumor associated microvasculature and tumor-associated 
fibroblasts, without collateral damage to normal cells and non-target organs. The 
observed reduction in tumor matrix production and tumor destruction paved the 
way for enhanced innate immune cell entry into the tumor microenvironment. 
The enhanced immune cells consist of cytotoxic T cells, NK cells, and dendritic 
cells for cell recognition, destruction and autoimmunization, as well as regulatory 
immune cells to prevent exaggerated immune responses that cause cytokine release 
syndrome or cytokine storm.
Hence, DeltaRex-G eradicates cancer cells without causing immune-mediated 
adverse events, an unwanted complication of immune checkpoint inhibitors such 
as ipilimumab, nivolumab, pembrolizumab, atezolizumab, etc. Conceivably, 
DeltaRex-G could also be used in combination with reduced doses of immune 
checkpoint inhibitors to minimize off-target toxicity (imAEs) and maximize 
anticancer efficacy.
A second tumor-targeted retrovector, DeltaVax, displaying the same high-affin-
ity tumor-targeting motif as DeltaRex-G, but this immuno-vector—encoding both 
the GM-CSF gene and the pro-drug regulated HSV-tk gene, and allowing for per-
sonalized “pulsed” in situ vaccinations—demonstrated promising results in a small 
Phase I/II study conducted in Manila, Philippines with considerable clinical benefit: 
good quality of life and an 86% one year survival rate in patients with advanced 
chemotherapy-resistant Stage 4 malignancies and a uniformly poor prognosis.
In the era of precision medicine, with tumor-targeted cancer gene therapy and 
immunotherapy coming of age, these recent advances bring great optimism to the 
medical and scientific communities around the world and the patients that they serve.
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